Cerus (CERS) Expected to Announce Earnings on Thursday

Cerus (NASDAQ:CERS) is anticipated to post its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Cerus to post earnings of ($0.0133) per share and revenue of $62.90 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02. The company had revenue of $59.89 million for the quarter, compared to analysts’ expectations of $55.68 million. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%. On average, analysts expect Cerus to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Price Performance

NASDAQ CERS opened at $2.92 on Wednesday. The company has a 50 day simple moving average of $2.87 and a 200-day simple moving average of $2.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.63 and a quick ratio of 1.06. The firm has a market capitalization of $585.08 million, a price-to-earnings ratio of -58.40 and a beta of 1.77. Cerus has a 52-week low of $1.15 and a 52-week high of $3.47.

Insider Activity at Cerus

In other news, CFO Kevin Dennis Green sold 33,676 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $2.94, for a total transaction of $99,007.44. Following the transaction, the chief financial officer owned 1,062,188 shares in the company, valued at approximately $3,122,832.72. This trade represents a 3.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Chrystal Jensen sold 24,329 shares of Cerus stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $2.94, for a total transaction of $71,527.26. Following the completion of the sale, the insider directly owned 966,657 shares of the company’s stock, valued at approximately $2,841,971.58. The trade was a 2.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 256,071 shares of company stock worth $747,894 over the last quarter. 5.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CERS. Captrust Financial Advisors lifted its holdings in Cerus by 15.3% in the 4th quarter. Captrust Financial Advisors now owns 37,051 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 4,916 shares during the last quarter. Brevan Howard Capital Management LP grew its holdings in Cerus by 228.1% during the second quarter. Brevan Howard Capital Management LP now owns 47,823 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 33,249 shares during the last quarter. Voleon Capital Management LP bought a new position in shares of Cerus in the third quarter valued at approximately $65,000. Mercer Global Advisors Inc. ADV lifted its stake in shares of Cerus by 133.1% in the third quarter. Mercer Global Advisors Inc. ADV now owns 35,692 shares of the biotechnology company’s stock worth $57,000 after buying an additional 20,378 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new stake in shares of Cerus in the third quarter worth $50,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CERS shares. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Zacks Research raised shares of Cerus from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 30th. BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Friday, May 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $4.00.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.